Evidence of FOXM1 having a significant role in DNA damage response, cancer drug resistance and its overexpression associated with GBM tumorigenicity, make it a promising and potential radiosensitizing target for GBM therapy. The gene discussed is FOXM1; the disease is glioblastoma.